Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCS-01 in inflammation and pain following cataract surgery
NCT05147233Phase 3Completed
- Sponsor
- Oculis
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of OCS-01 in post-operative inflammation, post-operative ocular pain, sponsored by Oculis. Started Jun 2022; status: completed.
02
Drugs
OCS-01
03
Conditions
post-operative inflammationpost-operative ocular pain
Beyond the preview
Go deeper on NCT05147233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147233.